Poletto E, Colella P, Pimentel Vera L, Khan S, Tomatsu S, Baldo G, et al. Improved engraftment and therapeutic efficacy by human genome-edited hematopoietic stem cells with Busulfan-based myeloablation. Mol Ther Methods Clin Dev. 2022;25:392-409 pubmed publisher

Pan C, Wu Q, Wang S, Mei Z, Zhang L, Gao X, et al. Combination with Toll-like receptor 4 (TLR4) agonist reverses GITR agonism mediated M2 polarization of macrophage in Hepatocellular carcinoma. Oncoimmunology. 2022;11:2073010 pubmed publisher

Hickman T, Choi E, Whiteman K, Muralidharan S, Pai T, Johnson T, et al. BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity. PLoS ONE. 2022;17:e0266980 pubmed publisher

Vavassori V, Mercuri E, Marcovecchio G, Castiello M, Schiroli G, Albano L, et al. Modeling, optimization, and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper-IgM syndrome. EMBO Mol Med. 2021;13:e13545 pubmed publisher